Latest Industry Insights

Technology Networks recently spoke with Mike Sherman, Chief Executive Officer at Chimerix to learn more about the company’s oncology, biodefense and COVID-19 therapeutic efforts.

In efforts to find efficacious interventions against SARS-CoV-2, the novel coronavirus that causes COVID-19, hundreds of clinical trials have been designed and launched at an unprecedented rate across the globe. As data emerges from these studies there is an urgent need to track progress, to ensure transparent communication of findings, and to avoid duplication of efforts. Technology Networks spoke with Cytel’s Edward Mills, Vice President of Real-World Evidence and Senior Principal Scientist, to learn more about the global COVID-19 Trial Tracker the company has recently launched.

Technology Networks recently spoke with Nick Milne, co-founder and CSO at Octarine to learn more about what science says on the therapeutic benefits of psychedelic compounds, why a bio-based approach for manufacturing is advantageous and the challenges associated.

Technology Networks recently had the pleasure of speaking to Dr Sandeep “Bobby” Reddy, Chief Medical Officer of NantHealth to gain a better understanding of the impact COVID-19 is having on the treatment of cancer. Reddy discusses what is currently known, in terms of risk and severity of SARS-CoV-2 infection in individuals with cancer, and elaborates on the innovative approaches that have been adopted by oncologists to enable continuation of high-quality care during the pandemic.

Advances in developing cell-based therapeutics and products require time-consuming and laborious cell-by-cell manipulation and analysis. Berkeley Lights Inc provide research and development services to help accelerate this process and make it more efficient via their proprietary technology. Technology Networks recently spoke with Mark White, Sr. Director of Marketing, Berkeley Lights Inc to find out more.

To try and make the process of applying for COVID-19 clinical trials easier, a free public health initiative called World Without COVID has been launched that will link users with all the trials they are eligible for.

London-based engineering startup Hadean, in collaboration with researchers at the Francis Crick Institute, hopes to use its simulation solution, the Aether Engine, to better model the spread of COVID-19 both between and within people. We spoke to Hadean’s Vice President of Operations, Mimi Keshani, to find out more.

The UK registered and self-funding charity LifeArc has several antibody–drug conjugate (ADC) programs in the oncology and non-oncology space. Technology Networks recently had the pleasure of speaking with Dr Laura Murch, Scientist at LifeArc, to learn more about ADCs. She highlights some of the antibody characterization assays they have developed to identify candidate ADCs, and touches on the regulatory success of ADCs.

Jagannath Swaminathan is the co-founder of Erisyon and a researcher at the Marcotte Lab at the University of Texas Austin. In this interview, we discuss the concept of next-generation protein sequencing, clinical proteomics and the critical role of protein sequencing in the fight against COVID-19.

Proteins are central to many disciplines within the life sciences, not least protein-based pharmaceuticals. Changes in protein conformation, structure or interactions could have significant impact on efficacy and safety. Therefore, being able to understand what forms of a protein are present in their natural conditions, even if present only at low levels, is important for analysts.